08:33 AM EST, 11/24/2025 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said Monday that it has reached the target enrollment of 6,000 participants in the US and UK for its phase 3 trial of CD388, a potential non-vaccine preventative of seasonal flu for patients at high risk of complications.

The company said the target population includes those who are immune compromised, have certain comorbidities, or are over 65 years old.

The study will evaluate the safety and efficacy of CD388, which will be administered as a single subcutaneous dose, Cidara said.

If the trial is successful, the company said it should be sufficient to support a biologics license application in high-risk populations.